A
correction
to this article has been published: Friedline et al., J. Exp. Med. 206 (3) 721
Published online
doi:10.1084/jem.20081811
The Journal of Experimental Medicine, Vol. 206, No. 2, 421-434
The Rockefeller University Press, 0022-1007 $30.00
© Friedline et al.
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Randall H. Friedline1,
David S. Brown1,
Hai Nguyen1,
Hardy Kornfeld2,
JinHee Lee2,
Yi Zhang3,
Mark Appleby4,
Sandy D. Der5,
Joonsoo Kang1, and
Cynthia A. Chambers1,
1 Department of Pathology, 2 Department of Medicine, Graduate Program in Immunology and Virology, University of Massachusetts Medical School, Worcester, MA 01655
3 Amgen, Inc., South San Francisco, CA 94080
4 Zymogenetics, Inc., Seattle, WA 98102
5 Department of Laboratory Medicine and Pathobiology, Program in Proteomics and Bioinformatics, University of Toronto, M5S 3G4 Toronto, Canada
CORRESPONDENCE Joonsoo Kang: Joonsoo.Kang{at}umassmed.edu
Cytotoxic T lymphocyte antigen-4 (CTLA-4) plays a critical role in negatively regulating T cell responses and has also been implicated in the development and function of natural FOXP3+ regulatory T cells. CTLA-4–deficient mice develop fatal, early onset lymphoproliferative disease. However, chimeric mice containing both CTLA-4–deficient and –sufficient bone marrow (BM)–derived cells do not develop disease, indicating that CTLA-4 can act in trans to maintain T cell self-tolerance. Using genetically mixed blastocyst and BM chimaeras as well as in vivo T cell transfer systems, we demonstrate that in vivo regulation of Ctla4–/– T cells in trans by CTLA-4–sufficient T cells is a reversible process that requires the persistent presence of FOXP3+ regulatory T cells with a diverse TCR repertoire. Based on gene expression studies, the regulatory T cells do not appear to act directly on T cells, suggesting they may instead modulate the stimulatory activities of antigen-presenting cells. These results demonstrate that CTLA-4 is absolutely required for FOXP3+ regulatory T cell function in vivo.
C.A. Chambers died on December 19, 2004.
Abbreviations used: Ab, antibody; CTLA4, cytotoxic T lymphocyte antigen-4; LCMV, lymphocytic choriomeningitis virus; Mtb, Mycobacterium tuberculosis.
© 2009 Friedline et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

CiteULike
Complore
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
-
Jain, N., Nguyen, H., Friedline, R. H., Malhotra, N., Brehm, M., Koyanagi, M., Bix, M., Cooper, J. A., Chambers, C. A., Kang, J.
(2009). Cutting Edge: Dab2 Is a FOXP3 Target Gene Required for Regulatory T Cell Function. J. Immunol.
183: 4192-4196
[Abstract]
[Full Text]
-
Kaufmann, D. E., Walker, B. D.
(2009). PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention. J. Immunol.
182: 5891-5897
[Abstract]
[Full Text]
-
Ghoreishi, M., Bach, P., Obst, J., Komba, M., Fleet, J. C., Dutz, J. P.
(2009). Expansion of Antigen-Specific Regulatory T Cells with the Topical Vitamin D Analog Calcipotriol. J. Immunol.
182: 6071-6078
[Abstract]
[Full Text]